Please try another search
For the nine months ended 31 March 2016, Transition Therapeutics Inc revenues was not reported. Net loss decreased 71% to C$10.7M. Lower net loss reflects Research and development - Balancing val decrease of 83% to C$5.4M (expense), Stock Compensation expense in R&D decrease of 77% to C$257K (expense), Salaries and benefits in R&D decrease of 32% to C$1.8M (expense).
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -2.78 | -2.88 | -6.13 | -13.44 |
Net Income | -4.18 | -2.01 | -4.49 | -13.99 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Assets | 33.09 | 37.78 | 41.06 | 49.65 |
Total Liabilities | 6.11 | 6.98 | 8.41 | 12.91 |
Total Equity | 26.98 | 30.8 | 32.66 | 36.74 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -16.94 | -14.79 | -10.95 | -47.8 |
Cash From Investing Activities | -0 | -0 | -0 | 2.24 |
Cash From Financing Activities | -0.01 | -0.01 | -0.01 | 26.18 |
Net Change in Cash | -15.74 | -11.44 | -8.71 | -16.7 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review